Naruszewicz M, Selinger E, Dufour R, Davignon J
Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Quebec, Canada.
Metabolism. 1992 Nov;41(11):1225-8. doi: 10.1016/0026-0495(92)90013-z.
Probucol, which decreases cholesterol levels and has antioxidant properties, was administered orally to patients with familial combined hyperlipidemia and high plasma lipoprotein(a) [Lp(a)] levels. The drug had no effect on Lp(a) concentrations after 4 weeks, but was found to be distributed in both Lp(a) and low-density lipoprotein (LDL). Before treatment, in each case LDL and Lp(a) isolated from the same individual were readily oxidized by copper, resulting in increased electrophoretic mobility and enhanced uptake and degradation by macrophages of both lipoproteins. After probucol treatment, both lipoproteins acquired resistance to in vitro oxidation by copper. Furthermore, probucol prevented their enhanced uptake and degradation by the macrophages. It is surmised that oxidized Lp(a) may carry an atherogenic potential that could be opposed by probucol administration.
普罗布考能降低胆固醇水平并具有抗氧化特性，将其口服给予家族性混合性高脂血症且血浆脂蛋白(a)[Lp(a)]水平高的患者。4周后该药物对Lp(a)浓度没有影响，但发现它分布于Lp(a)和低密度脂蛋白(LDL)中。治疗前，在每种情况下从同一个体分离出的LDL和Lp(a)都很容易被铜氧化，导致电泳迁移率增加以及两种脂蛋白被巨噬细胞摄取和降解增强。普罗布考治疗后，两种脂蛋白获得了对铜介导的体外氧化的抗性。此外，普罗布考阻止了它们被巨噬细胞增强摄取和降解。据推测，氧化的Lp(a)可能具有致动脉粥样硬化潜力，而普罗布考给药可能会对抗这种潜力。
